BioAge Labs

We are thrilled to announce the closing of BioAge's IPO! As of September 26, we are trading on Nasdaq as $BIOA. This milestone will enable our development of novel therapies that treat metabolic diseases by harnessing the biology of aging. Heartfelt thanks to the BioAge team for their brilliance and dedication, and to the investors and partners who believed in our vision and supported us on our journey. Together, they made this day possible. As we look to the future, we will continue to advance innovative treatments for the most prevalent and pressing health challenges of our time. Here’s to the next chapter, and to longer, healthier lives for all! Details: https://lnkd.in/g9kyj6xT

📸 BioAge’s stellar scientist (and VP of Translational Aging Biology) Yan Wang, PhD, at her #ObesityWeek2024 poster. In her presentation, Yan shared new preclinical data for our lead compound, the oral APJ agonist and exercise mimetic azelaprag. Her study showed that in mice on a high-fat diet, azelaprag increased weight loss and improved body composition in combination with rimonabant, an oral CB1 inverse agonist. The data demonstrate the potential of azelaprag to be complementary to a range of oral appetite suppression mechanisms for the treatment of obesity. Thanks to all who stopped by to talk science with Yan!

📸 Action shot! A great panel at BIO-EUROPE in Stockholm yesterday, where BioAge CBO Peng Leong joined biopharma leaders to explore the future of cardiometabolic therapy. Key insight: GLP-1 receptor agonists have opened new doors for healthspan therapeutics, creating opportunities for novel mechanisms like our exercise mimetic azelaprag. The next wave of cardiometabolic therapies may well come from targeting the biology of metabolic aging. Thanks to Brett Haumann of SV Health Investors, Birgit Steckel-Hamann of Eli Lilly and Company, and Ed Saltzman of Lumanity for a fascinating conversation!

Today at #ObesityWeek2024, BioAge's CMO Paul Rubin, MD will present new preclinical data on our lead program azelaprag, an oral agonist of the apelin receptor APJ. In his talk, Paul will show that in mice on a high-fat diet, azelaprag increased weight loss and improved body composition in combination with multiple oral appetite suppressants, including the oral GLP-1 drug danuglipron, supporting azelaprag’s potential alongside oral appetite suppressants. In addition, azelaprag monotherapy protected against excess weight gain and increased physical activity and energy expenditure, reinforcing the metabolic and exercise mimetic benefits of apelin signaling. If you're attending ObesityWeek, come by Paul's talk to learn more about how targeting the apelin pathway could complement existing—and future—obesity treatments. The Apelin Receptor Agonist Azelaprag Reduces Weight Gain & Improves Body Composition in Diet-Induced Obese Mice Wednesday, November 6, 2024, 8:45–9:00 am CST Corporate Orals Session 3, room 006 Press release: https://lnkd.in/gEbsd3bw

In her poster today at #ObesityWeek2024, BioAge’s VP Translational Aging Biology Yan Wang, PhD, will present new preclinical data on our lead program azelaprag, an oral agonist of the apelin receptor APJ. Yan's poster will show that in diet-induced obese mice, azelaprag increased weight loss and improved body composition in combination with the oral CB1 inverse agonist rimonabant, supporting azelaprag’s potential alongside oral appetite suppressants as a treatment for obesity. “The APJ Agonist Azelaprag Improves Weight Loss and Body Composition in DIO Mice on a CB1 Antagonist” Tuesday, November 5, 2024, 2:30 PM CST Poster number: 628 More details in our press release: https://lnkd.in/g68bnMDJ

At BIO-EUROPE in Stockholm today, BioAge Chief Business Officer Peng Leong will join other biopharma thought leaders in a discussion that delves into the future of cardiometabolic therapy. Following the advent of incretin drugs, the sector is on the lookout for novel cardiometabolic treatment modalities. The panel will explore novel approaches and emerging drug classes, including exercise mimetics, that could lead to novel therapies and address unmet needs beyond obesity. On the pane with Peng will be Brett Haumann of SV Health Investors and @Birgit Steckel-Hamann from Eli Lilly and Company, in a conversation moderated by Lumanity's Ed Saltzman. We're looking forward to a great conversation. If you’re attending BIO-EU, please join us! November 5, 2024 • 17:00 – 17:45 CET

BioAge will present new preclinical data on our oral obesity therapeutic azelaprag at #ObesityWeek2024, the world's leading scientific and clinical conference focused on obesity. Our CMO/EVP Resarch Paul Rubin and VP Translational Biology Yan Wang will show how azelaprag enhances weight loss when combined with various oral appetite suppressants, while also providing metabolic benefits as a monotherapy. These findings support our ongoing clinical development of azelaprag, and our broader mission to develop innovative treatments for metabolic diseases by leveraging insights from human aging biology. If you're attending ObesityWeek, visit Yan's poster on Tuesday afternoon or join us for Paul's talk on Wednesday morning to learn more about this promising approach to obesity treatment. https://lnkd.in/gEbsd3bw

📸 Action shot! On Saturday BioAge COO and co-founder Eric Morgen spoke at the 2024 Biomarkers of Aging Consortium Conference, showing how molecular profiling of human aging enabled us to discover and advance azelaprag, a promising exercise-mimetic drug now in Phase 2 trials, and highlighting the potential of aging biomarkers to predict therapeutic outcomes. Thanks to the organizers for an meeting of impressive breadth and depth, bringing a much-needed focus to a critical field.

On Saturday Nov 2 at the 2024 Biomarkers of Aging Consortium Conference, BioAge COO and co-founder Eric Morgen will give a talk showing how molecular profiling of human aging enabled us to discover and advance the apelin receptor agonist azelaprag, a promising exercise-mimetic drug now in Phase 2 clinical trials.

BioAge is proud to sponsor the 2024 Biomarkers of Aging Consortium conference, kicking off today in Boston! BoAC is the world’s premier meeting on the development of standardized, clinically validated tools to accurately measure the aging process and quantitatively evaluate the effects of healthspan-extending interventions in humans. As the field continues to progress and grow, establishing these standards is essential for advancing our understanding and ensuring the success of future innovations. Tickets are still available for a livestream of the Nov 2 sessions, including a talk by BioAge COO and co-founder Eric Morgen. Secure your livestream access here: https://lnkd.in/evdW9ea5